Market Overview

UPDATE: Piper Jaffray Raises PT on BioMarin Pharmaceutical on Positive Trial Results

Share:

In a report published Wednesday, Piper Jaffray analyst M Ian Somaiya reiterated an Overweight rating on BioMarin Pharmaceutical (NASDAQ: BMRN), and raised the price target from $64.00 to $70.00.

In the report, Somaiya noted, “BioMarin announced positive results from POM-001, the Phase I/II trial of BMN-701 in Pompe disease and confirmed its intention to advance ‘701 into Phase II/III by YE13. Overall, we believe the data are positive, with patients achieving meaningful improvements in pulmonary function and greater proportion of super responders in 6MWD. However, we believe the bar for success was relatively low, given go/no-go criteria outlined on the 4Q call and Myozyme's modest efficacy. Additionally, we note some variability in the data including lack of change in select pulmonary function measures (FVC).”

BioMarin Pharmaceutical closed on Tuesday at $60.76.

Latest Ratings for BMRN

DateFirmActionFromTo
Nov 2020SVB LeerinkReiteratesOutperform
Sep 2020Truist SecuritiesMaintainsBuy
Aug 2020Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

 

Related Articles (BMRN)

View Comments and Join the Discussion!

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
NTNXNeedhamMaintains43.0
HUTHC Wainwright & Co.Initiates Coverage On14.0
IMABPiper SandlerInitiates Coverage On75.0
MMSINeedhamMaintains68.0
CHRSHC Wainwright & Co.Maintains29.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com